Abstract Body

Background: More than 300,000 infants become vertically-infected with HIV-1 annually, despite the availability of effective antiretroviral prophylaxis regimens. Immunologic interventions, such as a maternal or infant vaccine, will likely be required to eliminate pediatric HIV-1. Immune correlates of risk of HIV-1 acquisition were identified in the moderately-successful RV144 HIV-1 vaccine trial, including the potentially-protective Envelope (Env) variable regions 1 and 2 (V1V2) IgGresponse. In this study, we aimed to define whether the potentially-protective responses identified in the RV144 vaccine trial or other Env-specific antibody responses would also predict the risk of mother to child HIV-1 transmission (MTCT). Methodology: Utilizing the Women and Infants Transmission Study (WITS) cohort of U.S., nonbreastfeeding HIV-infected mothers, which began enrolling prior to the availability of antiretroviral prophylaxis, we selected untreated, HIV-transmitting mothers (n = 83; 52% peripartum, 13% in utero and 35% unknown transmission mode) and a clinically-matched group of nontransmitting mothers (n = 165) with plasma samples available between 25 weeks of gestation and 2 months postpartum. A pilot study revealed no significant differences in the Env-specific humoral responses during this peripartum period. We utilized a multivariable logistic regression model to determine whether plasma IgG and IgA Env binding responses (including V1V2 and V3 regions), neutralizing antibody score, avidity, and antibody-dependent cell cytoxicity predicted the risk of MTCT. Results: Application of a primary immune variable model adapted from that applied to the RV144 trial revealed that neither the maternal Env V1V2 IgG response nor the Env breadth IgA score correlated with the risk of MTCT. However, assessment of additional binding antibody responses revealed that IgG responses against Env V3 correlated with the risk of MTCT (OR: 0.76, p = 0.04, q = 0.15). On secondary analysis, neutralizing antibody responses against tier 1 clade B variants MN and SF162 significantly correlated with the risk of peripartum transmission (OR: 0.54, p = 0.005, q = 0.1 for both). Finally, avidity of the IgG response against gp140 directly interacted with IgG responses against gp41, gp120, and V3 to predict the risk of MTCT (p = 0.01, q = 0.17-0.19). Conclusions: Maternal Env V3 IgG and neutralizing responses inversely correlated with transmission risk of MTCT, revealing distinctions between humoral immune correlates of risk of MTCT and vaccine-elicited humoral immune correlates of risk of sexual HIV-1 transmission identified in the RV144 trial.